focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Share News (ONC)

Share Price Information for Oncimmune (ONC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 24.50
Bid: 23.00
Ask: 26.00
Change: 0.00 (0.00%)
Spread: 3.00 (13.043%)
Open: 24.50
High: 0.00
Low: 0.00
Prev. Close: 24.50
ONC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Elixirr meets guidance, in strong start to 2023

Mon, 27th Feb 2023 10:37

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Elixirr International PLC, up 20% at 503.0 pence, 12-month range 412p-780p. The consultancy firm says 2022 was a strong year, with all metrics to be "in line or above" market expectations. Revenue is expected to rise 40% to GBP70.7 million, within previous guidance, and adjusted earnings before interest, tax, depreciation and amortisation is expected at GBP20.4 million - which is in line with Elixirr's guidance of exceeding GBP20 million. Says 2023 has started "strongly" with an acceleration of organic growth in the first quarter, and January seeing record monthly revenue.

----------

Directa Plus PLC, up 10% at 87p, 12-month range 76p-87p. The graphene nanoplatelet products producer and supplier says revenue in 2022 is now expected at not less than EUR10.8 million, which is up from EUR10.0 million communicated back in December's trading update. This represents a 25% increase year-on-year. Says momentum has continued into 2023, with trading meeting market expectations, which Directa cites as revenue of EUR13.5 million for the year.

----------

AIM - LOSERS

----------

Hercules Site Services PLC, down 38% at 44.99p, 12-month range 40p-73p. The labour supply company for the UK infrastructure sector raises GBP1.7 million in a placing of 3.8 million shares at issue price of 45p - which represents a 24% discount to Friday's closing price of 59p. "With a strong 2023 pipeline in place, these funds will support further organic growth in our Labour Supply division, which represented over 67% of our revenue in 2022," says Chief Executive Brusk Korkmaz.

----------

Oncimmune Holdings PLC, down 23% at 42p, 12-month range 36.69p-146.0p. The immuno-diagnostics developer says, in the 15 months to August 31, revenue was GBP3.8 million, little changed from GBP3.7 million in the year to May 31. Pretax loss widens to GBP11.6 million from GBP6.1 million across the same time frame. However, says revenue in the first six months of financial 2023 are expected to exceed GBP3.8 million, and it expects to be operating cashflow positive during the year.

----------

Forward Partners Group PLC, down 6.5% at 36p, 12-month range 35p-98.4p. The early-stage technology-focused investor says the fair value of its portfolio fell 40% to no less than GBP79.0 million at December 31, from GBP117.1 million a year before. Net asset value per share is expected to plunge to 71.0p from 104p a year before. The investment firm blamed valuation headwinds, "due to public market and macroeconomic pressures". "Despite the pressure on valuations many of them still grew rapidly," says Chief Executive Nic Brisbourne.

----------

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
17 Feb 2022 22:13

TRADING UPDATES: Novacyt gets UK approval; Nostra spuds Cypress well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued Thursday and not separately reported by Alliance News:

Read more
17 Feb 2022 09:09

Oncimmune's EarlyCDT Lung test granted approval by Ministry of Health for Aragon

(Sharecast News) - Immunodiagnostics group Oncimmune Holdings said on Thursday that its EarlyCDT Lung test had been granted approval by the Ministry of Health for Aragon in Spain and will now be adopted in the University Hospital Miguel Servet in Zaragoza.

Read more
15 Feb 2022 22:16

TRADING UPDATES: Burford, Frenkel Topping expect contrasting results

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
31 Dec 2021 11:20

Oncimmune reports fresh research from Cedars-Sinai Covid study

(Sharecast News) - Oncimmune announced the publication of a paper arising from the research collaboration with Cedars-Sinai Medical Center in Los Angeles on Friday, focusing on the sex-specific autoimmune reactivity to SARS-CoV-2 - the virus which causes Covid-19 - following mildly symptomatic infection.

Read more
31 Dec 2021 08:32

Oncimmune study suggests antibodies spike following Covid infection

Oncimmune study suggests antibodies spike following Covid infection

Read more
21 Dec 2021 14:25

Oncimmune shares up after multiple commercial contract wins

Oncimmune shares up after multiple commercial contract wins

Read more
21 Dec 2021 13:07

Oncimmune signs new commercial contracts

(Sharecast News) - Oncimmune Holdings announced on Tuesday that it has signed further commercial contracts within its 'ImmunoINSIGHTS' pharma services business.

Read more
19 Nov 2021 16:06

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
2 Nov 2021 15:55

TRADING UPDATES: Annual profit rises for UP Global Sourcing, Beximco

TRADING UPDATES: Annual profit rises for UP Global Sourcing, Beximco

Read more
2 Nov 2021 09:57

AIM WINNERS & LOSERS: Warpaint sees profit topping market forecasts

AIM WINNERS & LOSERS: Warpaint sees profit topping market forecasts

Read more
29 Oct 2021 15:57

EXECUTIVE CHANGES: TP chair resigns amid pressure from Science Group

EXECUTIVE CHANGES: TP chair resigns amid pressure from Science Group

Read more
26 Oct 2021 16:03

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
20 Sep 2021 13:47

Oncimmune inks profiling contract with unnamed global pharma company

Oncimmune inks profiling contract with unnamed global pharma company

Read more
20 Sep 2021 11:24

Oncimmune inks deal with global pharma firm

(Sharecast News) - Immunodiagnostics company Oncimmune has signed an autoantibody profiling agreement with an unnamed global pharmaceutical company, it announced on Monday, to evaluate the autoantibody profiles of patient samples in various autoimmune diseases.

Read more
23 Aug 2021 15:12

Oncimmune upbeat on three-year lung cancer test study

(Sharecast News) - Immunodiagnostics group Oncimmune announced the pre-publication of the three-year follow-up data for the 'Early detection of Cancer of the Lung Scotland' (ECLS) trial on Monday, which showed that after three years, the number of late-stage cancers and deaths were lower in patients tested with the 'EarlyCDT Lung' blood test.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.